Today: 21 May 2026
Novanta stock dives nearly 6% today as 2026 starts — why NOVT is lagging peers
2 January 2026
1 min read

Novanta stock dives nearly 6% today as 2026 starts — why NOVT is lagging peers

NEW YORK, Jan 2, 2026, 15:29 ET — Regular session

  • Novanta shares fell about 6% in afternoon trading, reversing after an early pop.
  • The stock lagged photonics peers that were up about 5%.
  • Investors are watching Jan. 14 management presentations and the next earnings timing for 2026 clues.

Novanta Inc shares were down 5.9% at $111.99 in afternoon trading on Friday, after opening near $119.89 and sliding to a session low of $110.46. The stock last traded about $7 lower on the day, with about 435,000 shares changing hands.

The drop matters because it came on the first trading day of 2026, when portfolio rebalancing can amplify moves in mid-cap industrial technology names.

It also stood out against gains in related laser and photonics stocks, leaving Novanta as a laggard even as investors chased strength elsewhere in the market.

Broader U.S. stocks were mixed as 2026 got underway, with chip shares among the bright spots, Reuters reported. “Stocks trade expensive on 18 of 20 measures, and we see elevated risks to the index level in the near term,” Savita Subramanian, Bank of America’s equity and quant strategist, wrote in a note cited by Reuters. Reuters

Novanta’s decline contrasted with gains in peers Coherent, IPG Photonics and MKS Instruments, which were up about 5% each in afternoon trading.

Novanta supplies core technology solutions used by medical, life science and advanced industrial original equipment manufacturers, the company says. It has businesses spanning precision medicine, precision manufacturing and robotics and automation.

Investors have a near-term checkpoint on Jan. 14, when Chair and Chief Executive Officer Matthijs Glastra and Chief Financial Officer Robert Buckley are scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference in San Francisco, the company said.

The same day, Chief Operating Officer Chuck Ravetto is set to participate in the CJS Securities “New Ideas for the New Year” investor conference, which the company said will be held virtually. Business Wire

With no fresh company news listed after the mid-December conference announcements, traders are likely to treat those January events as the next chance for management to address demand trends across medical and industrial end markets and any 2026 watchpoints.

Stock Market Today

  • SpaceX Set to Go Public: Key Details and Market Impact
    May 20, 2026, 8:02 PM EDT. SpaceX, founded by Elon Musk, is poised to go public, joining hundreds of companies that raised $70 billion in U.S. equity markets last year. Going public means the company will offer shares for sale on stock exchanges, allowing investors to buy ownership stakes. This move could unlock significant capital for SpaceX's ambitious space ventures, while providing early investors a chance to realize gains. The offering is closely watched amid a strong appetite for tech and aerospace stocks, reflecting broader market interest in innovation-driven firms.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal
Previous Story

Hubble spots odd triple jets on interstellar comet 3I/ATLAS as radio search finds no alien signal

Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention
Next Story

Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention

Go toTop